Transgene

Transaction marks Van Lanschot Kempen’s sixth transaction for a French Life Sciences company in the last 12 months, with >€1.25bn raised, underpinning the ability of Van Lanschot Kempen to support companies in the region at scale across equity, (venture) debt and royalty financing

• Transgene, a clinical-stage biotechnology company focused on developing targeted immunotherapies for the treatment of cancer, successfully raised c. €105m in equity financing via an accelerated bookbuild offering 
• The transaction was launched following a market sounding exercise, which resulted in visibility on indications of interest in excess of the total deal size prior to launch
• The order book, which was opened for a 24 hour period, was oversubscribed at the placement price, with strong demand from existing shareholders and several new international and local specialized healthcare investors joining the raise 
• Concurrent to the capital increase, Transgene carried out a public offering intended for retail investors via the PrimaryBid platform 
• Transgene intends to use the proceeds to enable the acceleration of the development of the myvac® program, the company’s platform for individualized therapeutic cancer vaccines, and extend its financial visibility until early 2028
• This transaction marks Van Lanschot Kempen's seventh ECM LS&H transaction for the year in a leading role, underscoring our expertise and deep network of specialized international investors to support our client's capital raising goals 

Transgene (Euronext: TNG) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for the treatment of cancer. The company’s lead asset TG4050 is the first individualized therapeutic vaccine based on the myvac® platform, currently in Phase 2 - with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient specific mutations, identified and selected through advanced artificial intelligence technologies.

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the SEK 672 million capital increase by Hansa Biopharma
• Joint Bookrunner in the USD 345 million Capital Increase by uniQure*
• Joint Bookrunner in the secondary sell-down of existing BioArctic shares for SEK 720 million
• Co-Manager in the USD 110 million financing by Oculis*
• Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programmes to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax*
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris*
• Lead Manager in the USD 345 million Capital Increase by Merus*
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing*
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma*
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank

The transactions above marked with “*” were conducted by Van Lanschot Kempen (USA) Inc. as underwriter